Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2009 Aug;32(8):1384-90.
doi: 10.2337/dc08-1987. Epub 2009 May 12.

New definition for the partial remission period in children and adolescents with type 1 diabetes

Affiliations
Multicenter Study

New definition for the partial remission period in children and adolescents with type 1 diabetes

Henrik B Mortensen et al. Diabetes Care. 2009 Aug.

Abstract

OBJECTIVE To find a simple definition of partial remission in type 1 diabetes that reflects both residual beta-cell function and efficacy of insulin treatment. RESEARCH DESIGN AND METHODS A total of 275 patients aged <16 years were followed from onset of type 1 diabetes. After 1, 6, and 12 months, stimulated C-peptide during a challenge was used as a measure of residual beta-cell function. RESULTS By multiple regression analysis, a negative association between stimulated C-peptide and A1C (regression coefficient -0.21, P < 0.001) and insulin dose (-0.94, P < 0.001) was shown. These results suggested the definition of an insulin dose-adjusted A1C (IDAA1C) as A1C (percent) + [4 x insulin dose (units per kilogram per 24 h)]. A calculated IDAA1C < or =9 corresponding to a predicted stimulated C-peptide >300 pmol/l was used to define partial remission. The IDAA1C < or =9 had a significantly higher agreement (P < 0.001) with residual beta-cell function than use of a definition of A1C < or =7.5%. Between 6 and 12 months after diagnosis, for IDAA1C < or =9 only 1 patient entered partial remission and 61 patients ended partial remission, for A1C < or =7.5% 15 patients entered partial remission and 53 ended, for a definition of insulin dose < or =0.5 units . kg(-1) . 24 h(-1) 5 patients entered partial remission and 66 ended, and for stimulated C-peptide (>300 pmol/l) 9 patients entered partial remission and 49 ended. IDAA1C at 6 months has good predictive power for stimulated C-peptide concentrations after both 6 and 12 months. CONCLUSIONS A new definition of partial remission is proposed, including both glycemic control and insulin dose. It reflects residual beta-cell function and has better stability compared with the conventional definitions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A: The thresholds for partial remission based on IDAA1C ≤9 (solid green line) and A1C ≤7.5% and insulin doses ≤0.5 units · kg−1 · 24 h−1 (rectangular dashed box). Each diagonal red line corresponds to one IDAA1C value. The numbers in boxes are the predicted values for stimulated C-peptide concentrations for a 10-year-old boy at the relevant IDAA1C value and, as illustrated, other threshold values for IDAA1C correspond to different predicted C-peptide values. The + signs give the distribution of 257 patients with type 1 diabetes after 6 months' duration. B: Age at onset influences the rate of partial remission as assessed by IDAA1C in children with type 1 diabetes. The proportion of partial remission is lowest in the youngest age-group (0–;4.9 years). Because of lower insulin sensitivity, the proportions of partial remission in the old age-group (≥10 years) and the school-age children (5–;9.9 years) seem to be similar despite higher residual β-cell function. C: The proportion of children in partial remission according to the different definitions. From 3 to 12 months, the curves for IDAA1C (curve 1), C-peptide (curve 2), and insulin dose (curve 4) show close agreement. Using the new definition, partial remission occurred in 61% at 3 months, in 44% at 6 months, and in 18% after 12 months. D: Agreement between definitions of those in partial remission, A1C ≤7.5% (left panel, dashed vertical line), IDAA1C ≤9 (right panel, dashed vertical line), and stimulated C-peptide >300 pmol/l (dashed horizontal line) at 12 months. The arrows point to the areas showing that A1C ≤7.5% disagrees significantly more than IDAA1C ≤9 with C-peptide >300 pmol/l, probably because the children receive more exogenous insulin, which is accounted for in the insulin dose–;adjusted model. E: The relationship of IDAA1C ≤9 (dashed vertical line) and stimulated C-peptide >300 pmol/l (dashed horizontal line) at 6 and 12 months. Individual observations are shown by age-groups. The regression lines for 6 (——) and 12 (– – –) months show the linear correlation of IDAA1C and C-peptide over a continuum of stimulated C-peptide values.
Figure 1
Figure 1
A: The thresholds for partial remission based on IDAA1C ≤9 (solid green line) and A1C ≤7.5% and insulin doses ≤0.5 units · kg−1 · 24 h−1 (rectangular dashed box). Each diagonal red line corresponds to one IDAA1C value. The numbers in boxes are the predicted values for stimulated C-peptide concentrations for a 10-year-old boy at the relevant IDAA1C value and, as illustrated, other threshold values for IDAA1C correspond to different predicted C-peptide values. The + signs give the distribution of 257 patients with type 1 diabetes after 6 months' duration. B: Age at onset influences the rate of partial remission as assessed by IDAA1C in children with type 1 diabetes. The proportion of partial remission is lowest in the youngest age-group (0–;4.9 years). Because of lower insulin sensitivity, the proportions of partial remission in the old age-group (≥10 years) and the school-age children (5–;9.9 years) seem to be similar despite higher residual β-cell function. C: The proportion of children in partial remission according to the different definitions. From 3 to 12 months, the curves for IDAA1C (curve 1), C-peptide (curve 2), and insulin dose (curve 4) show close agreement. Using the new definition, partial remission occurred in 61% at 3 months, in 44% at 6 months, and in 18% after 12 months. D: Agreement between definitions of those in partial remission, A1C ≤7.5% (left panel, dashed vertical line), IDAA1C ≤9 (right panel, dashed vertical line), and stimulated C-peptide >300 pmol/l (dashed horizontal line) at 12 months. The arrows point to the areas showing that A1C ≤7.5% disagrees significantly more than IDAA1C ≤9 with C-peptide >300 pmol/l, probably because the children receive more exogenous insulin, which is accounted for in the insulin dose–;adjusted model. E: The relationship of IDAA1C ≤9 (dashed vertical line) and stimulated C-peptide >300 pmol/l (dashed horizontal line) at 6 and 12 months. Individual observations are shown by age-groups. The regression lines for 6 (——) and 12 (– – –) months show the linear correlation of IDAA1C and C-peptide over a continuum of stimulated C-peptide values.

References

    1. Buyukgebiz A, Cemeroglu AP, Bober E, Mohn A, Chiarelli F: Factors influencing remission phase in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001; 14: 1585– 1596 - PubMed
    1. Akirav E, Kushner JA, Herold KC: β-Cell mass and type 1 diabetes: going, going, gone? Diabetes 2008; 57: 2883– 2888 - PMC - PubMed
    1. Hramiak IM, Dupre J, Finegood DT: Determinants of clinical remission in recent-onset IDDM. Diabetes Care 1993; 16: 125– 132 - PubMed
    1. Muhammad BJ, Swift PGF, Raymond NT, Botha JL: Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child 1999; 80: 367– 369 - PMC - PubMed
    1. Kordonouri O, Danne T, Enders I, Weber B: Does the long-term clinical course of type I diabetes mellitus differ in patients with prepubertal and pubertal onset? Results of the Berlin Retinopathy Study. Eur J Pediatr 1998; 157: 202– 207 - PubMed

Publication types

MeSH terms